For healthy adults aged 70 or older without heart disease, taking a low dose of aspirin every day does not reduce the risk of serious heart problems over time, even though there was a small temporary...
Mechanism
Synthesis from 1 study
Aspirin temporarily makes blood less likely to clot, but when you stop taking it, your blood becomes extra sticky, raising the risk of clots. At the same time, it weakens the stomach lining while you're taking it, causing bleeding. These two effects — more clots after stopping and more bleeding...
Most probable mechanism
Taking aspirin daily stops platelets from clumping too easily, which might seem helpful, but when the drug is stopped, the platelets overreact and clump more than before, increasing the risk of blood clots. At the same time, aspirin weakens the stomach's natural defenses, making bleeding more likely during treatment, but those defenses recover quickly after stopping. Over time, the harm from bleeding and the rebound clotting cancel out any early benefit, leaving no net protection against heart attacks or strokes.
Aspirin irreversibly blocks the enzyme cyclooxygenase-1 in platelets, preventing the production of thromboxane A2, a molecule that promotes platelet activation and aggregation.
During continuous use, reduced thromboxane A2 lowers platelet clumping, temporarily decreasing the likelihood of arterial blockages.
Upon discontinuation, newly formed platelets with fully active cyclooxygenase-1 enter circulation, leading to a surge in thromboxane A2 production and heightened platelet reactivity.
The surge in thromboxane A2 causes excessive platelet aggregation and vasoconstriction, increasing the risk of arterial thrombosis that can trigger heart attacks or ischemic strokes.
Aspirin also inhibits cyclooxygenase-1 in the stomach lining, reducing protective prostaglandins that maintain mucus secretion, blood flow, and acid neutralization.
This loss of mucosal protection increases vulnerability to erosion and bleeding in the upper gastrointestinal tract during active treatment.
After aspirin is stopped, cyclooxygenase-1 activity in the stomach recovers rapidly, restoring prostaglandin synthesis and mucosal defense within weeks.
The transient reduction in clotting during treatment is offset by the increased risk of bleeding during use and rebound clotting after discontinuation, resulting in no long-term net benefit for preventing cardiovascular events.
Evidence from Studies
Supporting (1)
Community contributions welcome
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.